ulcerative colitis

Showing 15 posts of 26 posts found.

OSE Immunotherapies’ UC drug gets DSMB positive recommendation

July 6, 2023
Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …

Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis

July 4, 2023
Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis

A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …


Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis

August 11, 2020
Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis

Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …


Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …


NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …


Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …


Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …


Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …


Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

October 22, 2018
Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …


Janssen’s Stelara shows promise across two dosages in ulcerative colitis

October 9, 2018
Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis

Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …


MSD’s ulcerative colitis drug scores expanded indication in Europe

July 9, 2018
Sales and Marketing Europe, MSD, pharma, ulcerative colitis

New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in …


Takeda’s Entyvio secures Japanese approval in ulcerative colitis

July 2, 2018
Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis

Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …

Latest content